Seer (SEER) Competitors

Standard BioTools (NASDAQ:LAB) and Seer (NASDAQ:SEER) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings, risk and community ranking.

Do analysts rate LAB or SEER?

Standard BioTools presently has a consensus target price of $2.50, suggesting a potential upside of 140.38%. Seer has a consensus target price of $3.00, suggesting a potential upside of 44.23%. Given Standard BioTools' stronger consensus rating and higher probable upside, analysts clearly believe Standard BioTools is more favorable than Seer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Standard BioTools	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Seer	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Which has higher valuation & earnings, LAB or SEER?

Standard BioTools has higher revenue and earnings than Seer. Standard BioTools is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Standard BioTools	$169.69M	2.33	-$74.66M	-$0.35	-2.97
Seer	$15.06M	8.26	-$86.28M	-$1.41	-1.48

Do institutionals & insiders believe in LAB or SEER?

53.7% of Standard BioTools shares are owned by institutional investors. Comparatively, 75.2% of Seer shares are owned by institutional investors. 23.2% of Standard BioTools shares are owned by company insiders. Comparatively, 15.0% of Seer shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Does the media prefer LAB or SEER?

In the previous week, Seer had 6 more articles in the media than Standard BioTools. MarketBeat recorded 7 mentions for Seer and 1 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 1.67 beat Seer's score of 0.28 indicating that Standard BioTools is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Standard BioTools	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Seer	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Which has more risk & volatility, LAB or SEER?

Standard BioTools has a beta of 1.8, suggesting that its stock price is 80% more volatile than the S&P 500. Comparatively, Seer has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500.

Is LAB or SEER more profitable?

Standard BioTools has a net margin of -79.92% compared to Seer's net margin of -565.83%. Seer's return on equity of -21.96% beat Standard BioTools' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Standard BioTools	-79.92%	-27.05%	-15.52%
Seer	-565.83%	-21.96%	-19.85%

Does the MarketBeat Community believe in LAB or SEER?

Standard BioTools received 2 more outperform votes than Seer when rated by MarketBeat users. Likewise, 83.33% of users gave Standard BioTools an outperform vote while only 13.64% of users gave Seer an outperform vote.

Company	Underperform	Outperform
Standard BioTools	Outperform Votes 5 83.33%	Underperform Votes 1 16.67%
Seer	Outperform Votes 3 13.64%	Underperform Votes 19 86.36%

Summary

Standard BioTools beats Seer on 14 of the 18 factors compared between the two stocks.